COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01188408
Recruitment Status : Withdrawn (Study shut-down in 12/2010 when NeoPharm merged with Insys.)
First Posted : August 25, 2010
Last Update Posted : March 12, 2018
Information provided by:
INSYS Therapeutics Inc

Brief Summary:

LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of metastatic castrate resistant prostate cancer (CRPC) and other variety of cancers. Taxotere has poor solubility and is designed to be administered with Tween 80 in ethanol. This vehicle causes acute hypersensitivity reaction. By removing toxic detergent used in Taxotere, the form of LE-DT, shows reduced toxicity and comparable therapeutic efficacy in pre-clinical study. The clinical evidence obtained from the NeoPharm Phase I study shows fewer side effects and possibly administered at higher dose to induce greater effectiveness of LE-DT. The current Phase II study is designed to accomplish the following objectives:

  1. Assess the antitumor effect indicator serum prostate specific antigen (PSA) following the intravenous (IV) administration of 110 mg/m2 LE-DT every three weeks in patients with metastatic castrate resistant prostate cancer
  2. To evaluate the measurable soft tissue disease response using the response evaluation criteria in solid tumor (RECIST) methodology
  3. To evaluate the progression-free survival (PFS) and overall survival (OS)
  4. To correlate PSA expression with tumor response
  5. To evaluate the safety of LE-DT at 110 mg/m2 level, in particular peripheral neuropathy, water retention as well as myelotoxicity
  6. To evaluate the quality of life (QOL)

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Liposome Entrapped Docetaxel (LE-DT) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Study Start Date : June 2010
Estimated Primary Completion Date : September 2011
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Liposome Entrapped Docetaxel (LE-DT)
Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
Drug: Liposome Entrapped Docetaxel (LE-DT)
110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
Other Names:
  • LE-DT
  • Liposomal Docetaxel

Primary Outcome Measures :
  1. Assessment of serum PSA [ Time Frame: 1 year ]
    Measure serum PSA after 2, 4 and 6 cycles of treatment

Secondary Outcome Measures :
  1. RECIST method assessment [ Time Frame: 1 year ]
    Measurable soft tissue disease response based on the RECIST method, PFS, and OS will also be assessed after 2, 4 and 6 cycle to determine the treatment effectiveness with LE-DT after treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be 18 years or older and male.
  2. Have histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.
  3. Patients without evidence of PSA progression must have clinical or radiographic evidence of metastatic disease.
  4. Must have castrate levels of testosterone (serum testosterone less than 50ng/dl) by either being on androgen ablation therapy with a luteinizing hormone-releasing hormone (LHRH) agonist or have had a prior bilateral orchiectomy.
  5. Patients must have documented evidence of disease progression: progressive disease is defined as a minimum of three consecutive elevations in PSA each obtained a minimum of one week apart with the last value being greater than 2 ng/mL and/or new metastatic lesions on bone scan (minimum of 2) and/or new or progressive disease on CT or MRI scan.
  6. For patients on an antiandrogen (flutamide, nilutamide, bicalutamide)

    1. If given as part of first line therapy or for patients who did respond to antiandrogen second line therapy, the patient must demonstrate progression of disease at least 4 weeks beyond discontinuation of such agents to rule out an antiandrogen withdrawal response.
    2. If given as a second line therapy and the patient did not respond or had a decline in PSA for less than 3 months, it is not required to observe for a withdrawal response.
  7. Chemotherapy-naïve patients (unlimited prior regimens of hormonal therapy are acceptable).
  8. Have no other malignancy within the past five years, except non-melanoma, skin cancer.
  9. Have recovered from acute toxicities of prior treatment:

    1. Greater than or equal to 4 weeks must have elapsed since receiving hormonal therapy (except for chronic non-investigational gonadotropin releasing hormone analogs or other primary androgen suppressive therapy which are required), biologic agents or any investigational agent (palliative bisphosphonate therapy for bone pain can be administered as clinically indicated).
    2. Greater than or equal to 4 weeks must have elapsed since receiving any radiotherapy
    3. Greater than or equal to 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy.
  10. Have the following hematology levels at Baseline:

    1. Absolute Neutrophil Count (ANC) greater than or equal to1,500 x 106 cells/L
    2. Platelets greater than or equal to 100 x 109 cells/L
    3. Hemoglobin greater than or equal to 9 g/L.
  11. Have the following chemistry levels at Baseline:

    1. AST (SGOT), ALT (SGPT) less than or equal to 1.5 x ULN
    2. Total bilirubin less than or equal to 1.5 ULN
    3. Creatinine less than or equal to 1.5 ULN; or 24-hour creatinine clearance greater than 60 mL/min
    4. Normal serum electrolytes and magnesium levels
  12. Have a life expectancy of greater than or equal to 12 weeks.
  13. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.
  14. Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee (EC)/Institutional Review Board (IRB)-approved written informed consent form (ICF) prior to receiving any study related procedure.

Exclusion Criteria:

  1. Patient has radiographic evidence of active (symptomatic, untreated) intraparenchymal brain metastases; any meningeal metastases; or asymptomatic untreated intraparenchymal brain metastases requiring treatment.
  2. Patient has received prior chemotherapy for metastatic prostate cancer.
  3. Patient has a known infection with human immunodeficiency virus or active viral hepatitis.
  4. Patient has active heart disease including myocardial infarction or congestive heart failure within the previous 6 months, symptomatic coronary artery disease, or uncontrolled arrhythmias.
  5. Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug (e.g., uncontrolled bleeding or bleeding diathesis).
  6. Any active infection requiring parenteral or oral antibiotics.
  7. Patient treated with any of the following:

    1. Taxol, Taxotere or Abraxane for prostate cancer or any prior malignancy
    2. Concurrent radiation therapy (except for palliative radiotherapy for symptomatic bone metastasis which can be administered as clinically indicated)
  8. Patient has pre-existing peripheral neuropathy of Grade greater than 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01188408

Layout table for location information
United States, District of Columbia
Georgetown University Medical center
Washington, District of Columbia, United States, 20007
United States, Oregon
Providence Portland Medical center
Portland, Oregon, United States, 97213-2933
Sponsors and Collaborators
INSYS Therapeutics Inc
Layout table for investigator information
Principal Investigator: Nancy A Dawson, M.D. Georgetown University
Principal Investigator: Brendan D Curti, M.D. Providence Health & Services

Layout table for additonal information
Responsible Party: Aquilur Rahman, NeoPhram, Inc. Identifier: NCT01188408    
Other Study ID Numbers: LE-DT 201
First Posted: August 25, 2010    Key Record Dates
Last Update Posted: March 12, 2018
Last Verified: March 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action